Fennec Pharmaceuticals is a biopharmaceutical company focused on its product candidate, PEDMARK® (sodium thiosulfate injection), which is used to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. Co. has established Fennec HEARS, a single source program designed to connect PEDMARK® patients to both patient financial and product access support. The program provides assistance and resources, regardless of insurance type, that can address co-pays or lack of coverage when certain eligibility requirements are met. The FENC stock yearly return is shown above.
The yearly return on the FENC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FENC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|